Barclays’s MBX Biosciences MBX Stock Holding History

Barclays’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.01M	Buy	136,652 +48,798	+56%	+$3.06M	﹤0.01%	1767
2026 Q2	$4.85M	Buy	87,854 +76,016	+642%	+$2.65M	﹤0.01%	1861
2026 Q1	$353K	Sell	11,838 -40,853	-78%	-$1.39M	﹤0.01%	3375
2025 Q4	$1.66M	Buy	52,691 +31,065	+144%	+$754K	﹤0.01%	3063
2025 Q3	$378K	Sell	21,626 -36,915	-63%	-$494K	﹤0.01%	3969
2025 Q2	$668K	Buy	58,541 +46,723	+395%	+$476K	﹤0.01%	3590
2025 Q1	$87.2K	Sell	11,818 -5,615	-32%	-$59.4K	﹤0.01%	4453
2024 Q4	$321K	Buy	17,433 +1,033	+6%	+$22K	﹤0.01%	4082
2024 Q3	$426K	Buy	+16,400	New	+$375K	﹤0.01%	3879

Other funds holding MBX

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Barclays's MBX Position: Q3 2026 in Review

Barclays increased its MBX Biosciences (MBX) stake by 56% in Q3 2026, buying an estimated $3.06M and bringing the position to 136,652 shares worth $8.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1767.

Barclays first reported a position in MBX in Q3 2024 and has held it in 9 quarters since. 59 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

Barclays held 136,652 shares of MBX Biosciences worth $8.01M as of Q3 2026.
Barclays bought 48,798 MBX Biosciences shares in Q3 2026, an estimated $3.06M.
MBX Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1767 holding.
Barclays first reported a position in MBX Biosciences in Q3 2024 and has held it in 9 quarters since.
59 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.